Search Icon
XFOR Archived Articles

X4 Pharmaceuticals: Delivering Innovation to Patients with Rare Immune Disorders

Published on November 27, 2024

X4 Pharmaceuticals, Inc. (NASDAQ:XFOR): Positive Interim Data from Ongoing Phase 2 Trial of Mavorixafor in Chronic Neutropenia Patients Supports Advancement to Phase 3

Published on September 24, 2024